1-3 of 3
Makoto Yoshioka
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 1745: Application of BET/CBP/p300 multi-bromodomain inhibitors as a novel therapeutic strategy for MLL-rearranged acute lymphoblastic leukemia

Free
Natsuki Imayoshi, Makoto Yoshioka, Shyh-Ming Yang, Koshi Akahane, Yuki Toda, Shigekuni Hosogi, Takeshi Inukai, Seiji Okada, David J. Maloney, Jefferey W. Strovel, Eishi Ashihara
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): 1745.
https://doi.org/10.1158/1538-7445.AM2020-1745
Published: 15 August 2020
View articletitled, Abstract 1745: Application of BET/CBP/p300 multi-bromodomain inhibitors as a novel therapeutic strategy for MLL-rearranged acute lymphoblastic leukemia
Journal Articles

Abstract 5062: Development of a first in class inhibitor of BET bromodomains and dopamine receptor 2

Free
Makoto Yoshioka, Jay Chauhan, Steven Fletcher, Jeffrey W. Strovel
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 5062.
https://doi.org/10.1158/1538-7445.AM2017-5062
Published: 01 July 2017
View articletitled, Abstract 5062: Development of a first in class inhibitor of BET bromodomains and dopamine receptor 2
Journal Articles

Gestational Age and Gender-specific In Utero V(D)J Recombinase-mediated Deletions

Free
Makoto Yoshioka, J. Patrick O’Neill, Pamela M. Vacek, Barry A. Finette
Journal: Cancer Research
Cancer Res (2001) 61 (8): 3432–3438.
Published: 15 April 2001
View articletitled, Gestational Age and Gender-specific In Utero V(D)J Recombinase-mediated Deletions
Open the PDF for Gestational Age and Gender-specific In Utero V(D)J Recombinase-mediated Deletions in another window